Table 3.
Safety of cabazitaxel, cases with data on white blood cell count and neutrophil count for the first and second courses of treatment (n = 37), excluding cases in which the cabazitaxel dose was reduced in the second course (n = 32).
| Median time to nadir of white blood cells (days, range) (n = 55) | 8, (5–10) | ||
| Median time to leukocyte ascent (days, range) (n = 55) |
2, (1–6) |
||
| Number of courses (n = 37) |
1st |
2nd |
p value |
| Nadir of white blood cells (/μl) (median, range) |
2140, (590–12820) | 4900, (780–19030) | 0.0013** |
| Grade 3/4 Leukopenia (cases, %) | G3: 8, (21.6) G4: 10, (27.0) |
G3: 4, (10.8) G4: 1, (2.7) |
˂ 0.001** |
| Nadir of neutrophils (median, range) | 763, (20-9700) | 3630, (120-14700) | ˂ 0.001** |
| Grade 3/4 neutropenia (cases, %) |
G3: 5, (13.5) G4: 15, (40.5) |
G3: 2, (5.4) G4: 3, (8.1) |
0.0021** |
| Number of courses (n = 32) |
1st |
2nd |
p value |
| Nadir of white blood cells (/μl) (median, range) |
2535, (730-12820) | 5100, (780-19030) | 0.0156* |
| Grade 3/4 leukopenia (Cases, %) | G3: 6, (18.8) G4: 8, (25.0) |
G3: 4, (12.5) G4: 1, (3.1) |
0.0051* |
| Nadir of neutrophils (median, range) | 1028, (20-9700) | 3662, (120-14700) | 0.0034** |
| Grade 3/4 neutropenia (cases, %) | G3: 5, (15.6) G4: 11, (34.4) |
G3: 2, (6.2) G4: 3, (9.3) |
˂ 0.001** |
*p < 0.05; **p < 0.005.